• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 5. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625

Introduction to 3-Bromo-2-cyano-5-(difluoromethyl)-4-methylpyridine (CAS No. 1805164-65-1)

3-Bromo-2-cyano-5-(difluoromethyl)-4-methylpyridine, identified by the CAS number 1805164-65-1, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and agrochemical research. This compound belongs to the pyridine family, a heterocyclic aromatic structure that is widely recognized for its diverse biological activities and synthetic utility. The presence of multiple functional groups, including a bromo substituent, a cyano group, a difluoromethyl moiety, and a methyl group, makes this compound a versatile intermediate in the synthesis of more complex molecules.

The structural features of 3-Bromo-2-cyano-5-(difluoromethyl)-4-methylpyridine contribute to its unique chemical properties and reactivity. The bromo group at the 3-position provides a handle for further functionalization via cross-coupling reactions, such as Suzuki or Buchwald-Hartwig couplings, which are essential in constructing biaryl structures found in many bioactive compounds. The cyano group at the 2-position can participate in nucleophilic addition reactions, enabling the formation of amides or carboxylic acids. Additionally, the difluoromethyl group enhances lipophilicity and metabolic stability, making it an attractive feature in drug design. The methyl group at the 4-position further influences the electronic distribution and steric environment of the molecule.

In recent years, there has been a growing interest in developing novel pyridine derivatives as pharmacological agents due to their broad spectrum of biological activities. 3-Bromo-2-cyano-5-(difluoromethyl)-4-methylpyridine has been explored as a key intermediate in the synthesis of various therapeutic compounds. For instance, researchers have utilized this compound to develop inhibitors targeting enzyme families involved in inflammatory pathways. The combination of electron-withdrawing and lipophilic groups in its structure allows for selective interactions with biological targets, making it a valuable building block for drug discovery.

One notable application of 3-Bromo-2-cyano-5-(difluoromethyl)-4-methylpyridine is in the synthesis of kinase inhibitors. Kinases are enzymes that play crucial roles in cell signaling pathways and are often implicated in diseases such as cancer and inflammatory disorders. By modifying the pyridine core with functional groups that enhance binding affinity and selectivity, researchers have been able to develop potent kinase inhibitors. The bromo and cyano groups provide opportunities for further derivatization, allowing for fine-tuning of the pharmacophore to achieve optimal activity against specific kinases.

The difluoromethyl group is particularly noteworthy due to its ability to improve pharmacokinetic properties such as bioavailability and metabolic stability. This feature has been extensively studied in medicinal chemistry, where it is often incorporated into drug candidates to enhance their efficacy and reduce off-target effects. In addition to kinase inhibitors, 3-Bromo-2-cyano-5-(difluoromethyl)-4-methylpyridine has been used in the development of antiviral agents. The structural motifs present in this compound can be modified to target viral proteases or polymerases, contributing to the design of novel antiviral therapies.

Recent advances in computational chemistry have also facilitated the exploration of 3-Bromo-2-cyano-5-(difluoromethyl)-4-methylpyridine as a lead compound. Through molecular docking simulations and virtual screening, researchers can predict potential binding interactions with biological targets, thereby accelerating the drug discovery process. These computational approaches have been particularly useful in identifying novel analogs with improved properties, such as enhanced solubility or reduced toxicity.

The agrochemical industry has also recognized the potential of 3-Bromo-2-cyano-5-(difluoromethyl)-4-methylpyridine as a precursor for developing new pesticides and herbicides. Pyridine derivatives are known for their efficacy against various pests and weeds due to their ability to disrupt essential biological processes. By leveraging the reactivity of functional groups like bromo and cyano, chemists can design molecules that target specific pests while minimizing environmental impact.

In conclusion,3-Bromo-2-cyano-5-(difluoromethyl)-4-methylpyridine (CAS No. 1805164-65-1) is a multifaceted compound with significant potential in pharmaceutical and agrochemical applications. Its unique structural features make it an invaluable intermediate for synthesizing biologically active molecules targeting various diseases. As research continues to uncover new therapeutic opportunities and refine synthetic methodologies,3-Bromo-2-cyano-5-(difluoromethyl)-4-methylpyridine is likely to remain at the forefront of medicinal chemistry innovation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)